Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Iressa black box sought

Executive Summary

Public Citizen requests that FDA add a black box warning to Iressa labeling "to state that the drug should be reserved for the same group of patients who were studied in the Phase II trial on which approval was based." FDA approved AstraZeneca's Iressa (gefitinib) for the treatment of advanced non-small cell lung cancer May 5 (1"The Pink Sheet" May 12, p. 3). A black box warning should communicate to "patient[s] that they may be at risk of a fatal lung disease unrelated to NSCLC," Public Citizen says in May 15 letter to Commissioner McClellan. FDA was understood to be considering a black box warning until very late in the review cycle for the drug...

You may also be interested in...

Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval

AstraZeneca's first chance to secure traditional approval for Iressa will be a randomized trial assessing symptom improvement in non-small cell lung cancer due to be submitted to the agency by June 2005

Medtechs Must Gear Up For New China Data Protection Rules

China ambitiously wants to champion domestic medtech manufacturers in the global market. It also needs to ensure foreign manufacturers do not sustainably dominate its home market – while also benefiting from their technical expertise, for the time being at least. Against that backdrop, new Chinese data laws are being eyed by global medtechs with a certain trepidation.

Zydus Knocked Back On Farxiga In US As Brand Continues To Grow

Zydus Cadila has failed to prove to a US court that a US patent expiring in October 2025 that shields AstraZeneca’s Farxiga (dapagliflozin) SGLT2 inhibitor is obvious, keeping the firm’s proposed ANDA product off of the market for now.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts